ClinicalTrials.gg
CompletedNCT05071612MARIPOSAUpdated Aug 12, 2026Results posted

Parallel Arm Trial of AD109 and AD504 In Patients With OSA

A Phase 2 interventional study of AD109 and AD504 in OSA - Obstructive Sleep Apnea, sponsored by Apnimed. Completed at 25 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Apnimed · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
294
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Sleep Apnea, Obstructive by Apnimed — 1 open to participants now, 1 under way, 1 of them phase 3. Sleep Apnea, Obstructive · Apnimed.

Enrollment
4th of 13
294 · median 60
Started
2021
with 2 others
Phase 2
9 of 13
none open now
Registered
7th of 13
by date

Among the 13 studies in Sleep Apnea, Obstructive by Apnimed, this one is the 4th largest by enrollment, is one of 3 that started in 2021, is one of 9 in phase 2, and was the 7th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

1 of the 13 studies in Sleep Apnea, Obstructive by Apnimed is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Sleep Apnea, Obstructive by Apnimed, or all of them as a file.
02

Study summary

This is a phase 2 randomized double-blind placebo-controlled parallel-arm dose finding study to compare fixed dose combinations of AD109 and AD504 to atomoxetine or placebo in Obstructive Sleep Apnea.

03

Conditions studied

  • OSA - Obstructive Sleep Apnea
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between 18 to 65 years of age for men and 18-75 for women, inclusive, at the Screening Visit.
  • Mean AHI 10 to 45 events/h, inclusive
  • PGI-S: >1
  • between 18.5 and 38 kg/m2 for men and 40 kg/m2 for women, inclusive.

Exclusion criteria

Exclusion Criteria:

  • Current sleep disorder other than OSA
  • Clinically significant craniofacial malformation.
  • Clinically significant cardiac disease (e.g. rhythm disturbances, coronary artery disease or heart failure or hypertension requiring more than 2 medications for control).
  • Participants with a history of using devices for OSA treatment, including CPAP, oral or nasal devices, or positional devices, may enroll as long as the devices have not been used for at least 2 weeks prior to first PSG and are not used during participation in the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
294 participants (actual)

Study arms

  • Experimental
    AD109 75/5mg

    Atomoxetine 75 mg/Aroxybutynin 5 mg tablet

    Drug: AD109

  • Experimental
    AD109 75/2.5mg

    Atomoxetine 75 mg/Aroxybutynin 2.5 mg tablet

    Drug: AD109

  • Experimental
    AD504 75/100mg

    Atomoxetine 75 mg tablet/Trazodone 100 mg capsule

    Drug: AD504

  • Experimental
    AD504 75/50mg

    Atomoxetine 75 mg tablet/Trazodone 50 mg capsule

    Drug: AD504

  • Active comparator
    Atomoxetine 75mg

    Atomoxetine 75 mg tablet

    Drug: Atomoxetine Hydrochloride

  • Active comparator
    Atomoxetine 75mg plus placebo

    Atomoxetine 75 mg tablet/placebo capsule

    Drug: Atomoxetine Hydrochloride

  • Placebo comparator
    Placebo tablet

    Drug: Placebo

  • Placebo comparator
    Placebo tablet plus placebo capsule

    Drug: Placebo

Interventions

  • DrugAD109

    Oral administration at bedtime

  • DrugAD504

    Oral administration at bedtime

  • DrugAtomoxetineStudies of AtomoxetineAtomoxetine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral administration at bedtime

  • DrugPlacebo

    Oral administration at bedtime

06

What researchers measure

Primary outcomes

  1. Change in Apnea-Hypopnea Index (AHI4) From Baseline: Combined AD109 Arms vs. Placebo

    Change in AHI4 (apnea-hypopnea index, 4% oxygen desaturation criterion; average respiratory events per hour of sleep) measured by in-lab polysomnography. Baseline was the mean of two pre-treatment PSG nights (Visits 2 and 3). Change from baseline was assessed at treatment PSG nights at approximately Day 21 (Visit 5) and Day 28 (Visit 6), modeled as repeated measures, with the reported value representing the model-based LS mean using equal (0.5/0.5) weighting between the Day 21 and Day 28 visits.

    Time frame: Baseline (mean of PSG Visits 2 and 3) to Day 21 and Day 28 (PSG Visits 5 and 6)

Secondary outcomes

  1. Change in Apnea-Hypopnea Index (AHI4) From Baseline: Combined AD504 Arms vs. Placebo

    Change in AHI4 (apnea-hypopnea index, 4% oxygen desaturation criterion; average respiratory events per hour of sleep) measured by in-lab polysomnography. Baseline was the mean of two pre-treatment PSG nights (Visits 2 and 3). Change from baseline was assessed at treatment PSG nights at approximately Day 21 (Visit 5) and Day 28 (Visit 6), modeled as repeated measures, with the reported value representing the model-based LS mean using equal (0.5/0.5) weighting between the Day 21 and Day 28 visits.

    Time frame: Baseline (mean of PSG Visits 2 and 3) to Day 21 and Day 28 (PSG Visits 5 and 6)

  2. Change in Apnea-Hypopnea Index (AHI4) From Baseline: Atomoxetine vs. Placebo

    Change in AHI4 (apnea-hypopnea index, 4% oxygen desaturation criterion; average respiratory events per hour of sleep) measured by in-lab polysomnography. Baseline was the mean of two pre-treatment PSG nights (Visits 2 and 3). Change from baseline was assessed at treatment PSG nights at approximately Day 21 (Visit 5) and Day 28 (Visit 6), modeled as repeated measures, with the reported value representing the model-based LS mean using equal (0.5/0.5) weighting between the Day 21 and Day 28 visits.

    Time frame: Baseline (mean of PSG Visits 2 and 3) to Day 21 and Day 28 (PSG Visits 5 and 6)

07

Results

Posted Aug 12, 2026
Limitations and caveats
This Phase 2 study was not powered to compare individual dose groups. Primary efficacy analyses evaluated prespecified pooled treatment groups, and results for individual dose arms should be interpreted descriptively.

Participant flow

Participant flow — Overall Study
MilestoneAD109 75/5mgAD109 75/2.5mgAD504 75/100mgAD504 75/50mgAtomoxetine 75mgPlacebo
Started414243406464
Completed353338384959
Not completed6952155
Withdrew: Adverse event5531121
Withdrew: Withdrawal by subject120101
Withdrew: Lost to follow-up000020
Withdrew: Protocol violation001002
Withdrew: Non-compliance with study drug010000
Withdrew: Other/unknown011011

Outcome measures

PrimaryChange in Apnea-Hypopnea Index (AHI4) From Baseline: Combined AD109 Arms vs. Placebo

Change in AHI4 (apnea-hypopnea index, 4% oxygen desaturation criterion; average respiratory events per hour of sleep) measured by in-lab polysomnography. Baseline was the mean of two pre-treatment PSG nights (Visits 2 and 3). Change from baseline was assessed at treatment PSG nights at approximately Day 21 (Visit 5) and Day 28 (Visit 6), modeled as repeated measures, with the reported value representing the model-based LS mean using equal (0.5/0.5) weighting between the Day 21 and Day 28 visits.

Time frame:
Baseline (mean of PSG Visits 2 and 3) to Day 21 and Day 28 (PSG Visits 5 and 6)
Reported as:
Least squares mean · events/hr
Change in Apnea-Hypopnea Index (AHI4) From Baseline: Combined AD109 Arms vs. Placebo
events/hrAD109 Combined Dose ArmsAD109 75/5mgAD109 75/2.5mgPlacebo
Change in Apnea-Hypopnea Index (AHI4) From Baseline: Combined AD109 Arms vs. Placebo-7.38 (-9.53 to -5.23)-7.40 (-10.41 to -4.38)-7.37 (-10.44 to -4.30)-0.21 (-2.49 to 2.07)
Statistical analysis
  • AD109 Combined Dose Arms vs Placebo · Mixed Models Analysis · p = <0.0001 (p-value is for two-sided test of the null hypothesis that the mean change from baseline is the same across the two treatments listing.) · Least squares mean difference: -7.17 · 95% CI -10.31 to -4.04LS mean difference between AD109 and placebo averaged across PSG Visits 5 and 6 (Days 21 and 28) using equal 0.5/0.5 weighting across AD109 dose levels per SAP v1.0.
SecondaryChange in Apnea-Hypopnea Index (AHI4) From Baseline: Combined AD504 Arms vs. Placebo

Change in AHI4 (apnea-hypopnea index, 4% oxygen desaturation criterion; average respiratory events per hour of sleep) measured by in-lab polysomnography. Baseline was the mean of two pre-treatment PSG nights (Visits 2 and 3). Change from baseline was assessed at treatment PSG nights at approximately Day 21 (Visit 5) and Day 28 (Visit 6), modeled as repeated measures, with the reported value representing the model-based LS mean using equal (0.5/0.5) weighting between the Day 21 and Day 28 visits.

Time frame:
Baseline (mean of PSG Visits 2 and 3) to Day 21 and Day 28 (PSG Visits 5 and 6)
Reported as:
Least squares mean · events/hr
Change in Apnea-Hypopnea Index (AHI4) From Baseline: Combined AD504 Arms vs. Placebo
events/hrAD504 Combined Dose ArmsAD504 75/100mgAD504 75/50mgPlacebo
Change in Apnea-Hypopnea Index (AHI4) From Baseline: Combined AD504 Arms vs. Placebo-8.02 (-9.98 to -6.05)-8.53 (-11.31 to -5.74)-7.50 (-10.29 to -4.72)-0.33 (-2.52 to 1.86)
Statistical analysis
  • AD504 Combined Dose Arms vs Placebo · Mixed Models Analysis · p = <0.0001 · Least squares mean difference: -7.68 · 95% CI -10.63 to -4.73LS mean difference between AD504 and placebo averaged across PSG Visits 5 and 6 (Days 21 and 28) using equal 0.5/0.5 weighting across AD504 dose levels per SAP v1.0.
SecondaryChange in Apnea-Hypopnea Index (AHI4) From Baseline: Atomoxetine vs. Placebo

Change in AHI4 (apnea-hypopnea index, 4% oxygen desaturation criterion; average respiratory events per hour of sleep) measured by in-lab polysomnography. Baseline was the mean of two pre-treatment PSG nights (Visits 2 and 3). Change from baseline was assessed at treatment PSG nights at approximately Day 21 (Visit 5) and Day 28 (Visit 6), modeled as repeated measures, with the reported value representing the model-based LS mean using equal (0.5/0.5) weighting between the Day 21 and Day 28 visits.

Time frame:
Baseline (mean of PSG Visits 2 and 3) to Day 21 and Day 28 (PSG Visits 5 and 6)
Reported as:
Least squares mean · events/hr
Change in Apnea-Hypopnea Index (AHI4) From Baseline: Atomoxetine vs. Placebo
events/hrAtomoxetine 75mgPlacebo
Change in Apnea-Hypopnea Index (AHI4) From Baseline: Atomoxetine vs. Placebo-5.40 (-7.93 to -2.87)-0.21 (-2.49 to 2.07)
Statistical analysis
  • Atomoxetine 75mg vs Placebo · Mixed Models Analysis · p = 0.003 · Least squares mean difference: -5.19 · 95% CI -8.59 to -1.78LS mean difference between Atomoxetine and placebo averaged across PSG Visits 5 and 6 (Days 21 and 28)

Adverse events

Collected over from randomization until end of study visit, up to 6 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AD109 75/5mg0/41 (0%)0/41 (0%)32/41 (78%)
AD109 75/2.5mg0/42 (0%)0/42 (0%)26/42 (61.9%)
AD504 75/100mg0/43 (0%)0/43 (0%)33/43 (76.7%)
AD504 75/50mg0/40 (0%)0/40 (0%)24/40 (60%)
Atomoxetine 75mg0/63 (0%)0/63 (0%)51/63 (81%)
Placebo0/63 (0%)0/63 (0%)25/63 (39.7%)
Most frequent other events
Showing 10 of 15
Most frequent other events
EventAD109 75/5mgAD109 75/2.5mgAD504 75/100mgAD504 75/50mgAtomoxetine 75mgPlacebo
Dry MouthGastrointestinal disorders24/4110/4218/4312/4020/6310/63
Middle InsomniaPsychiatric disorders4/418/422/431/4013/631/63
ConstipationGastrointestinal disorders5/410/427/433/402/632/63
NauseaGastrointestinal disorders4/415/423/433/404/632/63
Initial InsomniaPsychiatric disorders2/413/421/431/407/631/63
Urinary hesitationRenal and urinary disorders4/410/422/431/405/630/63
Decreased appetiteMetabolism and nutrition disorders4/412/421/430/405/631/63
InsomniaPsychiatric disorders3/410/420/431/403/630/63
Feeling jitteryGeneral disorders3/412/421/430/402/631/63
SomnolenceNervous system disorders3/411/421/431/400/631/63

Baseline characteristics

Safety Set population: all randomized participants who received at least one dose of study drug.

Age, Categorical
Age, Categorical(Participants)AD109 75/5mgAD109 75/2.5mgAD504 75/100mgAD504 75/50mgAtomoxetine 75mgPlaceboTotal
<=18 years0000000
Between 18 and 65 years374034375658262
>=65 years42937530
Age, Continuous
Age, Continuous(years)AD109 75/5mgAD109 75/2.5mgAD504 75/100mgAD504 75/50mgAtomoxetine 75mgPlaceboTotal
Mean54.2 ± 9.2451.5 ± 9.2257.8 ± 8.2053.9 ± 8.8152.8 ± 10.9554.9 ± 9.0354.2 ± 9.49
Sex: Female, Male
Sex: Female, Male(Participants)AD109 75/5mgAD109 75/2.5mgAD504 75/100mgAD504 75/50mgAtomoxetine 75mgPlaceboTotal
Female191722142227121
Male222521264136171
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AD109 75/5mgAD109 75/2.5mgAD504 75/100mgAD504 75/50mgAtomoxetine 75mgPlaceboTotal
American Indian or Alaska Native0010001
Asian22123515
Native Hawaiian or Other Pacific Islander0000000
Black or African American611555941
White332834315248226
More than one race0120104
Unknown or Not Reported0002215
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AD109 75/5mgAD109 75/2.5mgAD504 75/100mgAD504 75/50mgAtomoxetine 75mgPlaceboTotal
Hispanic or Latino9858121153
Not Hispanic or Latino323438325152239
Unknown or Not Reported0000000
Region of Enrollment
Region of Enrollment(participants)AD109 75/5mgAD109 75/2.5mgAD504 75/100mgAD504 75/50mgAtomoxetine 75mgPlaceboTotal
United States414243406363292
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m2)AD109 75/5mgAD109 75/2.5mgAD504 75/100mgAD504 75/50mgAtomoxetine 75mgPlaceboTotal
Mean31.12 ± 4.08533.43 ± 4.35230.89 ± 3.99932.68 ± 3.53731.16 ± 4.71631.17 ± 4.71931.65 ± 4.389
08

Study locations

25 sites
  • Santa Monica Clinical Trials
    Los Angeles, California 90025, United States
  • Pacific Research Network
    San Diego, California 92103, United States
  • SDS Clinical Trials, Inc.
    Santa Ana, California 92705, United States
  • Delta Waves
    Colorado Springs, Colorado 80918, United States
  • Teradan Clinical Trials
    Brandon, Florida 33511, United States
  • Research Centers of America -- Hollywood
    Hollywood, Florida 33024, United States
  • Sleep Medicine Specialists of South Florida
    Miami, Florida 33176, United States
  • NeuroTrials Research, Inc.
    Atlanta, Georgia 30328, United States
  • Chicago Research Center
    Chicago, Illinois 60634, United States
  • The Center for Sleep & Wake Disorders
    Chevy Chase, Maryland 20815, United States
  • Sleep Disorders Centers of the Mid-Atlantic (SDCMA)
    Glen Burnie, Maryland 21061, United States
  • Neurocare
    Newton, Massachusetts 02459, United States
  • Henry Ford Hospital
    Detroit, Michigan 48377, United States
  • Sleep and Attention Disorders Institute
    Sterling Heights, Michigan 48314, United States
  • Minnesota Lung Center / Minnesota Sleep Institute
    Woodbury, Minnesota 55125, United States
  • St. Luke's Hospital Sleep Medicine
    Chesterfield, Missouri 63017, United States
  • Clayton Sleep Institute
    Maplewood, Missouri 63143, United States
  • Clinilabs
    New York, New York 10016, United States
  • Coastal Carolina Health Care, P.A.
    New Bern, North Carolina 28562, United States
  • CTI Clinical Research Center
    Cincinnati, Ohio 45212, United States
  • Intrepid Research
    Cincinnati, Ohio 45245, United States
  • Brian Abaluck, LLC
    Malvern, Pennsylvania 19355, United States
  • Bogan Sleep Consultants LLC
    Columbia, South Carolina 29201, United States
  • Velocity Clinical Research
    Greenville, South Carolina 29615, United States
  • FutureSearch Trials of Neurology
    Austin, Texas 78731, United States
09

References and documents

Publications

  • Schweitzer PK, Taranto-Montemurro L, Ojile JM, Thein SG, Drake CL, Rosenberg R, Corser B, Abaluck B, Sangal RB, Maynard J. The Combination of Aroxybutynin and Atomoxetine in the Treatment of Obstructive Sleep Apnea (MARIPOSA): A Randomized Controlled Trial. Am J Respir Crit Care Med. 2023 Dec 15;208(12):1316-1327. doi: 10.1164/rccm.202306-1036OC. PubMed 37812772 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Jul 2022, 7 months.

Results were first posted in Aug 2026, 4 years after primary completion. A results delay was requested in Nov 2022.

Of 47 phase 2 interventional studies under Sleep Apnea, Obstructive, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 46. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2021
First posted
Oct 8, 2021
StartActual
Nov 29, 2021
Primary completionActual
Jul 20, 2022
CompletionActual
Aug 3, 2022
Results delay requested
Nov 30, 2022
Results first posted
Aug 12, 2026
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05071612
Lead sponsor
Apnimed
Responsible party
Sponsor
First posted
Oct 8, 2021
Start date
Nov 29, 2021
Primary completion
Jul 20, 2022
Completion
Aug 3, 2022
Results posted
Aug 12, 2026
Last update
Aug 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AD109

Start the discussion